In recent years, several studies at home and abroad have confirmed that compared to human insulin 50, menthol insulin 50 is effective in improving postprandial blood glucose either as a starting or intensive treatment regimen, and has good safety and high compliance. Domestic studies have confirmed that a high proportion of premixed insulin analogs are preferred for the treatment of Chinese patients with type 2 diabetes mellitus in line with their disease characteristics. In particular, menthol insulin 50 has fast onset of action, high peak attainment, good control of postprandial glucose, low risk of hypoglycemia and convenient application, which effectively makes up for the many shortcomings of human insulin 50. A recent head-to-head comparison study has confirmed that switching from human insulin 50 to menthol insulin 50 can significantly improve postprandial blood glucose in Chinese patients with type 2 diabetes and is well tolerated. The Expert Opinion on Clinical Application of Menthol Insulin 50 provides more detailed guidance on the individualized application of menthol insulin 50 in China. For Chinese people, especially in the case of high postprandial glucose, the application of Menthol Insulin 50 can be considered. Of course, with more experience in application, the application of Menthol Insulin 50 in China’s clinic will be further improved and optimized, and the treatment of Chinese diabetic patients is to gain greater benefits.